No association between use of tenofovir disoproxil fumarate, etravirine, or integrase-strand transfer inhibitors and acquisition or severe outcomes of SARS-CoV-2 infection in people with HIV in the Netherlands

AIDS. 2023 Jul 15;37(9):1481-1486. doi: 10.1097/QAD.0000000000003577. Epub 2023 Apr 13.

Abstract

In two Dutch observational cohorts of people with HIV, the use of TDF, ETR, or INSTIs was not independently associated with either the risk of incident SARS-CoV-2 infection or severe COVID-19 outcomes, as was suggested by previous observational and molecular docking studies. Our findings do not support a strategy of modifying antiretroviral therapy to include these agents to protect against SARS-CoV-2 infection and severe COVID-19 outcomes.

Trial registration: ClinicalTrials.gov NCT01466582.

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • COVID-19*
  • HIV Infections* / complications
  • HIV Infections* / drug therapy
  • Humans
  • Integrases / therapeutic use
  • Molecular Docking Simulation
  • Netherlands / epidemiology
  • SARS-CoV-2
  • Tenofovir / therapeutic use

Substances

  • Tenofovir
  • Anti-HIV Agents
  • etravirine
  • Integrases

Associated data

  • ClinicalTrials.gov/NCT01466582